Seaside Therapeutics Reports Positive Data From Phase 2 Study Of STX209 In Autism Spectrum Disorders

Seaside Therapeutics, Inc. announced positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD). The primary endpoint of the study, an improvement on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), achieved statistical significance (p